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Abstract: 
Objective: 
Determine the effects of dapagliflozin in patients with heart failure(HF) and 
type 2 diabetes(T2DM) on left ventricular(LV) remodelling using cardiac MRI. 
Research Design and Methods: 
We randomized 56 patients with T2DM and HF with LV systolic dysfunction 
to dapagliflozin 10mg daily or placebo for one year, on top of usual therapy. 
Primary endpoint was difference in LV end-systolic volume(LVESV) using 
cardiac MRI. Key secondary endpoints included other measures of LV 
remodelling, clinical and biochemical parameters.  
Results: 
In our cohort, Dapagliflozin had no effect on LVESV or any other parameter 
of LV remodelling. It however, reduced diastolic BP and loop diuretic 
requirements, while increasing hemoglobin, hematocrit and ketone bodies. 
There was a trend towards lower weight.  
Conclusions: 
We were unable to determine with certainty if dapagliflozin in patients with 
T2DM and HF had any effect on LV remodelling. Whether the benefits of 
dapagliflozin in HF are due to remodelling or other mechanisms remains 
unknown. 
Introduction:  
Type 2 diabetes mellitus(T2DM) and heart failure(HF) commonly co-exist 
and can be lethal.(1) The sodium-glucose linked transporter 2 inhibitor 
(SGLT2i) is a new class of diabetes therapy that reduces HF hospitalization 
and cardiovascular(CV) death.  
A meta-analysis of CV outcome trials of T2DM patients with varying CV risk 
(n=34,322) showed an overall 14% reduction in major adverse 
cardiovascular events and 24% reduction in composite of CV mortality and 
HF hospitalization.(2) In the DAPA-HF trial, dapagliflozin was compared 
against standard of care in 4744 patients with established HF and found a 
striking 30% reduction in HF hospitalization, 18% reduction in CV death and 
significant improvements in HF symptom burden.(3) 
SGLT2i clearly results in a significant reduction in HF risk, however the 
mechanism of these effects is unclear. The main objective of this work was 
to determine the cardiac effects of dapagliflozin in patients with HF and 
T2DM, to help explain the substantial improvements in HF outcomes seen in 
large clinical trials.  
 
Methods and design:  
The trial design and methods have been described previously.(4)  
Briefly, this single center, placebo-controlled clinical trial was designed to 
look for changes in three parameters of left ventricular (LV) remodelling (i.e. 
LV volumes, mass and ejection fraction) using cardiac magnetic resonance 
(CMR) imaging. 56 patients were randomized 1:1 to either dapagliflozin 
10mg/day or placebo for 1 year. Participants had a diagnosis of T2DM and 
history of symptomatic HF with a previously documented reduction in 
ejection fraction (EF) using echocardiography. They were on stable therapy 
for at least 3 months prior to recruitment, with a maximum loop diuretic dose 
of 80 mg/day and baseline eGFR of ≥ 45 mls/min/1.73m2. 
The primary outcome was change in LV end-systolic volume (LVESV). Key 
secondary outcomes included LV end-diastolic volume (LVEDV), indexed-LV 
mass (LVMI) and LVEF as well as a range of clinical and biochemical 
markers of HF. The CMR imaging protocol and reproducibility of analysis 
have been published previously.(5; 6)     
 Statistical analysis:  
Data was analyzed by intention to treat with single mean imputation of 
missing values. All continuous outcomes were analyzed using multiple linear 
regression, controlling for baseline values, age, sex and renal function. 
Categorical outcomes were analyzed using Pearson’s chi-square. A two-
sided p value of <0.05 was taken as significant. Analysis was performed 
using R version 3.4.3 for windows. 
 
Results:  
Mean age was 67.1 years, majority male (66.1%) with an average BMI of 
32.5 mg/m2. Majority (87.5%) were in NYHA functional class I or II, indicating 
mild HF, with the commonest etiology being ischemic heart disease. Mean 
baseline HbA1c was 60.9 mmol/mol (7.7%), and the mean estimated 
glomerular filtration rate (eGFR) was 72.0 ml/min/1.73 m2. Other baseline 
values are listed on Supplementary Table 1.  
After 1 year, there was no significant change in LVESV; +4.82 ml;(95%CI-
13.28-22.93) p=0.594. There was no effect on LVEDV; +7.83 ml;(95%CI-
15.05-30.70) p=0.495, LVMI; +2.5 g/m2;(95%CI-3.95-8.95) p=0.440 or LVEF 
+0.96%;(95%CI-3.32-4.69) p=0.732. (Table 1)  
Dapagliflozin significantly reduced diastolic blood pressure (BP); -8.15mmHg 
;(95%CI-13.02- -3.28) p=0.001, but there was no difference in systolic BP or 
heart rate.  
Dapagliflozin increased hemoglobin; +0.86 g/dl;(95%CI 0.27-1.46) p=0.005, 
hematocrit +2.89%; (95%CI 1.14 - 4.64) p=0.002 and fasting beta-
hydroxybutyrate (ketone body); +0.04 mmol/L;(95%CI 0.01-0.07) p=0.022. 
There was a trend towards lower weight; -2.26kg;(95%CI -4.83-0.31) 
p=0.083.  
Patients on dapagliflozin required less loop diuretic therapy; -29.06mg; 
(95%CI-42.17- -15.95) p<0.001 and were more likely to stop or reduce their 
loop diuretic dose; 53.6%vs10.7%; p=0.001.  
There was no significant difference in HbA1c or eGFR at the end of 1 year.  
 
 
 Adverse events:  
There were 5 deaths in total; 1 cancer death in the dapagliflozin arm, 1 
cancer and 3 cardiovascular deaths in the placebo arm.  
There were 3 acute coronary syndromes in the placebo arm but none in 
dapagliflozin arm. There was 1 HF hospitalization in each arm. There was no 
difference in the incidence of serious adverse events between the two arms.  
There were significantly more instances of major decline in renal function 
(sustained >20% increase in creatinine or eGFR <45 ml/min/1.73 m2) in the 
dapagliflozin arm compared to placebo; 28.6% vs 0% p=0.008. This was 
transient and resolved after reduction of loop diuretic dose without any 
change in dapagliflozin dose.  
 
Conclusions:  
In this mechanistic study of SGLT2i in patients with HF and T2DM, we 
observed that 1 year of dapagliflozin therapy did not reverse LV remodeling.  
However, we observed a significant difference in diastolic BP, loop diuretic 
requirements, hemoglobin, hematocrit and fasting ketone levels between 
groups. There was also a trend towards lower weight.  
Reversing LV remodelling is an important factor in reducing mortality and 
morbidity in patients with HF.(7; 8) Therefore, the apparent absence of an 
effect on LV remodelling in this study, if true, is intriguing given the striking 
improvements in HF outcomes demonstrated in large clinical trials of 
SGLT2i.  
The DAPA-HF trial showed a reduction in HF hospitalization (seen almost 
immediately) and mortality (seen later). The rapid onset of the hospitalization 
benefit is unlikely to be the result of LV remodeling, and it is postulated to be 
due to the diuretic effect of SGLT2i. We observed significantly reduced loop 
diuretic requirements in participants taking dapagliflozin, supporting this 
hypothesis. Reduced congestion due to osmotic diuresis is a plausible 
explanation for reduction in HF hospitalizations. This diuretic effect may also 
be responsible for the difference in the diastolic BP observed between 
groups. However, these effects cannot explain the substantial mortality 
benefits. Our findings suggest that other mechanisms should be considered, 
beyond the established paradigm of LV remodelling, to explain these effects 
of SGLT2i. Some secondary outcomes of this study may help guide future 
investigation into potential mechanisms. 
We observed significantly higher hemoglobin, hematocrit and fasting ketones 
in the dapagliflozin group. Although this has been seen in other preclinical 
and clinical trials of SGLT2i, we are the first to report this in the HF 
population. Preliminary research suggests that utilization of ketone bodies as 
an alternative fuel by cardiomyocytes may improve cardiac efficiency.(9) 
SGLT2i also increases erythropoietin production by renal cortical fibroblasts, 
contributing to increased hemoglobin and hematocrit, thereby potentially 
improving myocardial oxygenation.(10; 11) We did not, however, explore the 
effects of dapagliflozin on myocardial energetics or other direct cardiac 
effects that have been proposed by others.(12) Clearly, more work is 
needed. 
Our study is limited by the mild severity of HF and small sample size. This 
limits the certainty of our findings and makes the case for a larger, more 
adequately powered trial. Additionally, the adjustment of loop diuretic dose 
may have affected ventricular volume / loading as well. At the time of 
conceptualization of this study in 2014, there was little experience with the 
use of this drug class in patients with HF and concomitant loop diuretic. This 
led to a cautious selection of participants with milder HF, on modest doses of 
diuretics. Ongoing work in a similar trial investigating SGLT2 inhibition on LV 
remodeling with a different agent of this class (NCT03485092) will help 
validate our findings.   
In summary, we showed that 1 year of dapagliflozin therapy in patients with 
mild HF and T2DM reduced loop diuretic requirements but we did not detect 
any change in CMR measures of LV remodelling. This warrants further 
investigation to understand potentially novel mechanisms that may be 
responsible for its effect in improving HF outcomes. 
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Table 1. Primary and key secondary outcomes.   
Outcome Dapagliflozin (n=28) 
Placebo 
(n=28) 
Adjusted 
treatment 
effect 
p value 
 Mean (SD) Mean (SD) (95% CI)  
LVESV (ml) -8.9 (32.7) -18.8 (51.0) 4.82 (-13.28 to 22.93) 0.594 
Indexed 
LVESV 
(ml/m2) 
-4.5 (16.7) -10.5 (26.2) 2.49 (-6.30 to 11.28) 0.571 
LVEDV (ml) -7.7 (40.5) -24 (55.9) 7.83 (-15.05 to 30.70) 0.495 
Indexed 
LVEDV* 
(ml/m2) 
-4.3 (19.8) -13.4 (29.0) 3.9 (-7.05 to 14.85) 0.478 
LVEF (%) 2.6 (6.7) 1.4 (9.6) 0.69 (-3.32 to 4.69) 0.732 
LV Mass 
Index (g/m2) 4.0 (11.1) 0.6 (11.7) 
2.5 (-3.95 to 
8.95) 0.44 
LV Stroke 
Vol (ml) 0.0 (6.5) -2.9 (6.2) 
1.86 (-1.52 
to 5.24) 0.273 
Indexed LA 
Volume 
(ml/m2) 
-1.7 (13.5) -1.5 (15.0) -2.6 (-9.67 to 4.48) 0.464 
Weight (kg) -1.4 (4.4) 0.15 (6.0) -1.36 (-4.14 to 1.42) 0.329 
Weight† (kg) -1.9 (4) 0.73 (5.3) -2.26 (-4.83 to 0.31) 0.083 
SBP 
(mmHg) -2.6 (18.9) 3.6 (18.7) 
-4.7 (-14.51 
to 5.11) 0.34 
DBP 
(mmHg) -0.4 (7.4) 8.8 (11.9) 
-8.15 (-13.02 
to -3.28) 0.001 
Heart rate 
(beats/min) -4.6 (10.8) -1.3 (11.1) 
-2.26 (-7.88 
to 3.36) 0.424 
Hemoglobin 
(g/dL) 1.1 (1.1) 0.0 (1.4) 
0.86 (0.27 to 
1.46) 0.005 
Hematocrit 
(%) 4.0 (3.0) 0.0 (4.0) 
2.89 (1.14 to 
4.64) 0.002 
HbA1c 
(mmol/mol) -4.0 (10.4) -1.2 (11.6) 
-1.49 (-6.95 
to 3.97) 0.586 
BHB 
(mmol/L) 0.03 (0.06) 0 (0.06) 
0.04 (0.01 to 
0.07) 0.022 
Serum 
creatinine 
(µmol/L) 
5.3 (12.8) 4.6 (12.1) 1.46 (-5.56 to 8.47) 0.679 
eGFR -1.2 (12.0) -5.3 (13.1) 1.96 (-4.78 to 8.70) 0.563 
Loop 
diuretic 
dose‡ (mg) 
-16.0 (18.1) 12.3 (28.3) 
-29.06 (-
42.17 to -
15.95) 
<0.001 
 
Abbreviations: SD=Standard deviation; CI=Confidence interval; 
LVEDV=Left ventricular end diastolic volume; LVESV=Left ventricular end 
systolic volume; LVEF=Left ventricular ejection fraction; LV=Left ventricular; 
SBP=Systolic blood pressure; DBP=Diastolic blood pressure; BHB=Beta-
hydroxy butyrate;  
 
†=analysis excludes large outliers; 1 patient from each arm due to excessive 
weight gain and loss (see methods) –dapagliflozin (n=27), placebo (n=27);  
‡=Bumetanide dose converted to equivalent frusemide dose (1mg 
bumetanide=40mg frusemide)  
 
 
